Children have a mild course of acute COVID-19 in most of the cases. However, a few non-controlled studies on children present an evaluation of long-term recovery from SARS-CoV-2 infection. Mostly, the studies were conducted on a small sample size with children aged between 0-17 years.
The study aimed to evaluate symptoms and duration of 'long COVID' in children.
Data collection was done through a nationwide cohort study with 37,522 RT-PCR verified SARS-CoV-2 infected children, aged between 0-17 years (response rate 44.9%). Further, the study also had a group of 78,037 children as control (response rate 21.3%). An electronic questionnaire was used to collect data.
It was obtained that symptoms lasting > 4 weeks were common among both SARS-CoV-2 children and controls. However, SARS-CoV-2 infected children with the age of 6-17 years reported symptoms more frequently than the control group (percent difference 0.8%).
The most reported symptoms among pre-school children were
Fatigue Risk Difference (RD) 0.05 (CI 0.04-0.06)
Loss of smell RD 0.01 (CI 0.01-0.01)
Loss of taste RD 0.01 (CI 0.01-0.02)
Muscle weakness RD 0.01 (CI 0.00-0.01)
However, in school children, respiratory problems RD 0.03 (CI 0.03-0.04), dizziness RD 0.02 (CI 0.02-0.03), chest pain RD 0.01 (CI 0.01-0.01) were also observed along with the above-mentioned symptoms.
Furthermore, children in the control group experienced significantly more concentration difficulties, headache, muscle and joint pain, cough, nausea, diarrhea and fever than SARS-CoV-2 infected.
In most of the cases, 'long COVID' symptoms resolve in children within 1-5 months. Therefore, it can be interpreted that long COVID in children is rare and mainly of short duration.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Higher levels of HIF2α found to slow down aggressive childhood cancer
2.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
3.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer
1.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
Progressive Models in Hematology for Healthcare Excellence
4.
Quality of Life Following Organ Function Preserving Oncologic Innovation
5.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation